SEARCH

SEARCH BY CITATION

References

  • Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., Visani, G. & Tura, S. (2002) Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica, 87, 12861306.
  • Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D., Parker, J. & UK MDS Guidelines Group (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. British Journal of Haematology, 120, 187200.
  • Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F., Hills, R.K., Wheatley, K. & National Cancer Research Institute Haematological Oncology Study Group Adult Leukemia Working Party (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109, 11141124.
  • Cheson, B.D. & Simon, R. (1987) Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years’ experience. Seminars in Oncology, 14, 126133.
  • Detourmignies, L., Wattel, E., Lai, J.L., Bauters, F. & Fenaux, P. (1993) Is there a role for low-dose cytarabine arabinoside in de novo acute myeloid leukemia in the elderly? Annals of Hematology, 66, 235240.
  • Faderl, S., Ravandi, F., Huang, X., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Borthakur, G., Verstovsek, S., Thomas, D.A., Kwari, M. & Kantarjian, H.M. (2008) A randomized study of clofarabine plus low-dose cytarabine as front-line therapy for patients age 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 112, 16381645.
  • Fenaux, P., Lai, J.L., Gardin, C. & Bauters, F. (1990) Cytogenetics are a predictive factor of response to low-dose ara-C in acute myelogenous leukemia (AML) in the elderly. (Letter) Leukemia, 4, 312.
  • Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C.L., Silverman, L.R. & International Vidaza High-risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with conventional care regimens in higher-risk myelodysplastic syndromes: results of a randomised, phase III study. The Lancet Oncology, 10, 223232.
  • Gore, S.D., Baylin, S., Sugar, E., Carraway, H., Miller, C.B., Carducci, M., Grever, M., Galm, O., Dauses, T., Karp, J.E., Rudek, M.A., Zhao, M., Smith, B.D., Manning, J., Jiemjit, A., Mays, A., Zwiebel, J., Murgo, A., Weng, L.J. & Herman, G.J. (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Research, 66, 63616369.
  • Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 20792098.
  • Hellstrom-Lindberg, E., Robert, K.-H., Gahrton, G., Lindberg, G., Forsblom, A.-M., Kock, Y. & Ost, A. (1992) A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukemia. British Journal of Haematology, 81, 503511.
  • Housset, M., Daniel, M.T. & Degos, L. (1982) Small doses of ara-C in the treatment of acute myeloid leukemia: differentiation of myeloid leukemia cells? British Journal of Haematology, 51, 125129.
  • Kurzrock, R. (2002) Myelodysplastic syndrome overview. Seminars in Hematology, 39, 1825.
  • Leyden, M., Manoharan, A., Boyd, A., Cheng, Z.M. & Sullivan, J. (1984) Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction. British Journal of Haematology, 57, 301307.
  • Miller, K.B., Kyungmann, K., Morrison, F.S., Winter, J.N., Bennett, J.M., Neiman, R.S., Head, D.R., Cassileth, P.A. & O’Connell, M.J. (1992) The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Annals of Hematology, 65, 162168.
  • Mufti, G.J., Fenaux, P., Hellstrom-Lindberg, E., Santini, V., List, A.F., Gore, S., Seymour, J.F., Silverman, L.R., Backstrom, J. & Beach, C.L. (2008) Treatment of high-risk MDS patients (pts) with −7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): effects on overall survival (OS). Journal of Clinical Oncology, 26, 380s, Abstract 7033.
  • Nair, R., Nair, C.N. & Advani, S.H. (1998) All trans retinoic acid with low-dose cytosine arabinoside in the treatment of myelodysplastic syndrome. Leukemia & Lymphoma, 29, 187192.
  • Raj, K., John, A., Ho, A., Thomas, N.S.B. & Mufti, G.J. (2006) Early and sustained response to azacitidine occurs in high risk MDS patients with monosomy 7: responses correlate with increased apoptosis not CDKN2B demethylation. British Journal of Haematology, 133, 6162. Abstract 111.
  • Raj, K., John, A., Ho, A., Chronis, C., Khan, S., Samuel, J., Pomplun, S., Thomas, N.S.B. & Mufti, G.J. (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia, 21, 19371944.
  • Roboz, G.J., Ritchie, E.K., Curcio, T., Provenzano, J., Carlin, R., Samuel, M., Wittenberg, B., Mazumdar, M., Christos, P.J., Mathew, S., Allen-Bard, S. & Feldman, E.J. (2008) Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer, 113, 25042511.
  • Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., Ellerton, J., Larson, R.A., Schiffer, C.A. & Holland, J.F. (2002) Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. Journal of Clinical Oncology, 20, 24292440.
  • Visani, G., Malagola, M., Piccaluga, P.P. & Isidori, A. (2004) Low-dose ara-C for myelodysplastic syndromes: is it still a current therapy? Leukemia & Lymphoma, 45, 15311538.
  • Zwierzina, H., Suciu, S., Loeffler-Ragg, J., Neuwirtova, R., Fenaux, P., Becsak, M., Harousseau, J., Nuessler, V., Cermak, J., Solbu, G., Willemze, R., de Witte, T., Amadori, S. & EORTC Leukemia Cooperative Group (2005) Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia, 19, 19291933.